new Delhi: The Covid-19 Working Group of the National Technical Advisory Group on Immunization (NTAGI) has recommended the inclusion of Kovovax, manufactured by the Serum Institute, in the national immunization campaign for people aged 12 years and above.
According to a report in news agency PTI, official sources said on Sunday that the COVID Working Group has now recommended the addition of Kovovax to the national immunization program for people above 12 years of age from the permanent technical sub-committee of NTAGI.
Until now, drug dealers in India had approved Kovovax for restricted use in emergency situations in adults and in the 12-17 age group, subject to certain conditions.
Notably, Prakash Kumar Singh, Director of Government and Regulatory Affairs, Serum Institute of India (SII), had written to the Union Health Ministry requesting inclusion of Kovovax in the vaccination campaign.
“A meeting of the NTAGI’s COVID-19 Working Group was held on 1 April, during which data from Kovovax was reviewed, following which it was recommended that the vaccine be included in the national COVID-19 vaccination programme. , which is meant to vaccinate people aged 12 and above,” PTI quoted one of the sources as saying.
Singh had also said that the Pune-based firm wants to provide the vaccine to private hospitals at Rs 900 per dose plus GST and is awaiting directions to the Center to supply it.
However, the cost of Kovovax to the government was not mentioned.
It is noteworthy that from March 16, India started vaccinating children aged 12-14 years with the biological E.
In a letter to Union Health Secretary Rajesh Bhushan, Singh had reportedly said that private companies, educational institutions, social organisations, central government bodies and public sector undertakings are required to vaccinate their employees, families and children. were requesting.
“Under the visionary leadership of our CEO Adar C Poonawalla, we have developed, manufactured and received Emergency Use Authorization from our National Regulatory Authority for another world-class COVID-19 vaccine, Kovovax, on 28th December for 18 years and above, and on March 9, 2022 for children in the age group of 12 to 17 years,” an official source wrote in the letter to Singh.
See below health equipment-
Calculate your body mass index (BMI)